Quest Products addresses blue light exposure through daily supplement
PLEASANT PRAIRIE, Wis. — Quest Products has just launched Blue Guard Blue Light Defense Formula, a daily supplement formulated with Lutemax 2020 that helps protect and improve vision.
"We're all being exposed to more blue light than ever before, but the problem is especially concerning for millennials, who are at risk by constantly interacting with screens that can harm their vision," stated Mark McGreevy, VP business development for Quest Products. "With Blue Guard, anyone can reduce eye strain, increase eye speed, and improve overall eye health."
The active ingredient in Blue Guard is Lutemax 2020. Lutemax 2020 is formulated for optimal eye health with an optimal ratio of two key carotenoids — lutein, and zeaxanthin. Of the more than 600 carotenoids found in nature, lutein and zeaxanthin isomers are crucial to maintaining good eye health, specifically to the macula — a muscle located near the back of the eye whose job is to protect the retina from dangerous blue light waves.
Blue Guard defends against the immediate harmful effects of blue light, which include painful consequences such as eye strain, visual fatigue, decreased productivity, decreased ability to focus, increased stress and lack of sleep.
Blue light is the type of illumination given off by electronic screens, that through high exposure, is the most damaging light to your eyes. Those at risk can start feeling the short-term effects of over-exposure very quickly. With millennials often spending half the day or more in front of a computer or mobile phone, they are risking the early onset of eye problems.
Blue Guard defends against these conditions by strengthening the density of the macular pigment – increasing its natural density, which provides the protective layer in your eyes. Blue Guard filters out high-energy blue light, stops light waves, and defends against oxidative stress.
Blue Guard is a one-a-day supplement that can be taken with or without a meal.
The product is now available through the company's website and at Amazon, with more retailers anticipated shortly.
Upper respiratory, cold, allergy and sinus category sees ‘impressive’ growth
The upper respiratory, cold-allergy-sinus liquids and tablets segments combined saw a 4% growth in sales across multi-outlets for the last 12 months compared with the previous year, with growth in drug and food channels for both UR segments. Impressive growth of 7% from cold-allergy-sinus liquids in the drug channel was driven by manufacturer Reckitt Benckiser with 16% growth year over year (Figure 1).
The largest number of significant new products came from Pfizer in cold-allergy-sinus liquids during the last year, including four new products in its new Emergen-C sub-brand Energy+ and two new Immune+ Emergen-C products (Figure 2).
Margins for RB consistently were the highest in the mass, food and drug channels for cold-allergy-sinus tablets, while Bayer saw the lowest. For liquids, Pfizer saw the highest margins in the mass, food and drug channels, while P&G saw the lowest (Figure 3). GSK was the only major manufacturer in the upper respiratory cold-allergy-sinus segments that saw list price increases during the last 12 months, with 25 increases in total, averaging approximately 4%.
For cold-allergy-sinus liquids, P&G saw the largest amount of circular print ad support in the food channel, while RB saw the most support from drug retailers. For cold-allergy-sinus tablets, RB saw the largest count of ads in all three major channels. Overall, cold-allergy-sinus liquids were supported more than tablets (Figure 4).
To view the full Promo Watch report, complete with charts, click here.
CPR is a leading provider of competitive market intelligence and insights in the health, beauty and wellness industry. Learn more by visiting CompetitivePromotion.com.
Banking on natural trend, MusclePharm looks to expand retail penetration
DENVER — MusclePharm earlier this week reported significant progress towards expanding its reach through retail, thanks in part to the recent launch of its Natural Series, a line of plant-based, vegan, gluten-free, soy-free and non-GMO premium products that appeal to an expanding customer segment that seek organic alternatives to the traditional nutritional products and supplements.
"The launch of Natural Series has presented an opportunity for MusclePharm to expand not only its product range but also our distribution reach," Brian Casutto, EVP sales and operations, MusclePharm, told investors Monday. "One very positive development during the quarter was getting Natural Series into Sprouts Farmers Market," he said. "Sprouts is a major natural grocer and household name across the U.S. It operates 270 stores nationwide and is renowned for being a leader in the affordable and healthy food market which is exactly the consumer base Natural Series is targeting."
Beyond Sprouts, MusclePharm is in ongoing discussions with additional potential retailer distribution partners, Casutto said. "Our distribution strategy remains to drive MusclePharm products through both brick-and-mortar and online outlets. While brick-and-mortar stores continue to face challenges, we are confident that the broad rollout of Natural Series, combined with exciting upcoming new product launches, will drive the expanded sales through specialty retail channels and chains such as the Vitamin Shoppe."
Within the online segment, MusclePharm continued to see strength in online sales in the second quarter, driven by an expanded contribution of Amazon and several other online retailers. Amazon accounted for 12% of the company's total revenues in the second quarter, up from 6% in Q1 of 2017.